Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety Comparison of DWJ1511 and DWC202501 in Healthy Volunteers
NCT07144176Phase 1Recruiting
- Sponsor
- Daewoong Pharmaceutical
- Start
- Sep 2025
- Primary completion
- Sep 2025
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of DWJ1511 in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Daewoong Pharmaceutical. Primary endpoints: Area under the plasma drug concentration-time curve from time 0 to the last measurable concentration and Maximum plasma concentration. Started Sep 2025; status: recruiting.
02
Drugs
DWJ1511
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07144176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07144176.